Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0000950170-24-023292 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-29 | 2024-02-27 | KPTI | Mason Michael | EVP, CFO, Treas | S - Sale | $1.32 | -2,545 | 244.4K | -1% | -$3,359 | |
| 2024-02-29 | 2024-02-28 | KPTI | Mason Michael | EVP, CFO, Treas | A - Grant | $0.00 | +188.2K | 432.6K | +77% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-27 | S | D | 2,545 | $1.32 | 244,400 | D | — | — | (F1) This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ("RSUs"). The sale does not represent a discretionary trade by the reporting person. |
| 2 | Common | Common Stock | 2024-02-28 | A | A | 188,205 | $0.00 | 432,605 | D | — | — | (F2) Represents the award of RSUs pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2025. |